meet hurdl
john groetelaar good outcom sharehold meet
growth hurdl increas confid
pipelin acceler see potenti
upsid ep tax
john groetelaar right choic ceo role hill-rom announc
john groetelaar current presid intervent segment bd
becom presid ceo effect may view right choic
support decis view john heir appar tim
ring bard acquir bd experi run
multibillion dollar busi signific intern emerg market
acumen understand import innov hill-rom product
suit busi model differ evalu mr groetelaar abil
assess transform less clear think mani better
choic board expect updat strateg vision cover growth
margin capit deploy prioriti may unlik
novemb understand senior leader hill-rom given retent
bonus includ alton shader front line cautious
optimist disrupt amongst senior leadership minim
gener in-lin core growth hill-rom report
revenu bp vs mse reflect core growth line
guidanc expect patient support system pss growth
reflect declin us growth ex us growth
momentum acceler pt pt account neg one-
time item hurrican anniversari larg custom order ep
estim lower tax rate vs
mse driven stock comp drove beat stock pressur today
appear relat fundament issu quarter like tie
elev expect sector need upsid discuss
enough pleas see exhibit reconcili result vs mse
meet hurdl increas confid previous
discuss acceler key momentum hurdl year
come core growth core growth guidanc look achiev
us given impli pt momentum deceler midpoint vs
acceler saw pipelin contribut continu ramp
centrella manag indic backlog
expect mortara fulli organ accret growth
profil low-singl mid-singl digit growth busi discuss
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
pipelin detail encourag manag
commit durabl perform achiev guidanc
guidanc rais beat see potenti upsid tax hill-rom
maintain core revenu growth guidanc rais low end
ep guidanc rang vs prior essenti rais
beat vs guidanc gross margin guidanc rais bp
bp base strong perform manag reinvest
upsid behind new product launch flc product centrella channel
invest surgeri net oper margin still expect improv
bp y/i guidanc look achiev us year see potenti
upsid tax given averag rate guidanc impli
pipelin remain track deliv back half
previous discuss expect pipelin contribut pt core
growth year see hill-rom debat commentari pipelin
encourag manag continu see contribut
y/i growth year back half see centrella ramp
improv integr tabl motion traction uptak ophthalmolog front
line product retinavu vision help acceler pipelin
remain equal-weight pt discuss downgrad earlier
year continu see lrp achiev believ hill-rom
transform increasingli reflect consensu estim solid execut
drive multipl expans hill-rom price target remain
maintain ev/ebitda multipl estim reflect
turn discount smid cap coverag given higher leverag lower growth
multipl re-rat given divers improv growth
multipl re-rat given divers improv growth
price target reflect ev/ebitda multipl
turn discount smid cap med-tech given leverag lower
new product launch growth exceed expect cost initi
take margin higher new product launch perform better expect
underli margin surpass top hill-rom long-rang plan given upsid
welch allyn organ initi hill-rom manag remain focus
addit deal compani delev
hill-rom growth stabil mid-singl digit north america growth slow
given limit bed contribut tailwind welch allyn surgic
new product move hill-rom structur organ growth rate
welch allyn synergi mix cost initi drive margin
improv stabil growth visibl margin improv drive
long-term plan materi sale see moder growth
surgic solut see neg growth north america
moder organ initi materi manag expect leav
welch allyn driven improv mix synergi multipl fall given
compani high debt load
hill-rom multipl re-rat
growth move higher volatil
decreas hill-rom sale base
diversifi number driver
increas hill-rom organ
lrp achiev
achiev prior lrp target year earli
hill-rom new lrp call growth
trend toward
along oper margin
target see new lrp
achiev product pipelin
robust time around end market
mix improv
hospit capital-expenditure environ hill-
rom revenu expos hospit
centrella contribut
sale expect contribut
sale drive pt core growth
progress cost restructur on-going
uptak recent product launch
shift capital-expenditure spend environ
risk achiev price
futur sale lower expect
european sale continu declin
organ leverag prove difficult
materi shift capital-expenditure environ given
million except ep
good sold
dollar million except per share data
total revenu
less net incom non-controlling interest
net incom sharehold
dollar million except per share data
dollar million except per share data
invest invest secur
softwar net
note receiv net discount
accru pension postretir benefit
addit paid capit
dollar million except per share data
net realiz capit loss gain equiti method invest incom loss
provis defer incom tax
chang oper asset liabil
net provid oper activ
capit expenditur purchas intang
proce dispos properti equip leas
proce sale non-strateg asset
payment acquisit busi net cash
invest purchas capit call
proce invest sale matur
net use invest activ
net chang short-term debt net debt issuanc cost
payment long-term debt net proce settlement interest rate swap includ payment/borrow revolv
distribut non-controlling interest partner
net chang equiti
effect exchang rate ce
net chang
equival bop
equival eop
